Breast cancer, chemotherapy
Woman with breast cancer awareness ribbon

In a new study, it suggested that many women who have early-stage breast cancer can easily skip the chemotherapy without any danger in chances of beating the disease. This study is now said to be a landmark study which has used test the gauge of each patient’s risk.

The study shows that about 70 percent of women have diagnosed with this early stages of one of the most common forms of breast cancer which don’t need chemotherapy as the part of the treatment. The results of this study were presented at the American Society of Clinical Oncology meeting held in Chicago on Sunday.

The study which was published on Sunday in the New England Journal of Medicine has analyzed about the use of genetic test assessed cancer risk, and it is based on 21 genes which are linked to breast cancer recurrence.

According to the lead author Dr. Joseph A. Sparano, who is the associate director for clinical research at the Albert Einstein Cancer Center said that these data have confirmed of using a 21 gene expression test in order to assess the risk of the cancer recurrence which can spare women with unnecessary treatment if the test indicates that the chemotherapy will not give any benefit to them. The study was sponsored by the National Cancer Institute, and the ECOG-ACRIN Cancer Research Group led it.

The cancer care which has now been occurring has led away from the chemotherapy, older drugs which have harsh side effects and it favors in gene-targeting therapies, immune system treatment, and hormone blockers.

The study on breast cancer was focused on the cases where chemo’s value are increased and in doubt as women who have early-stage disease has not spread to lymph nodes, and they are hormone-positive and is not in the type of the drug Herceptin targets.

The new findings include estrogen-sensitive and tested negative for HER2 and have early stage tumors which are below five centimeters that have not spread to lymph nodes. They also have scored between 11 and 25 on the Oncotype DX Breast Recurrence Score Test. The research also shows that the women who have scored between 0 and ten can skip chemotherapy and who have scored above 25 have got benefitted from adding chemotherapy in their hormonal treatment plan.

LEAVE A REPLY

Please enter your comment!
Please enter your name here